Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SKIN
stocks logo

SKIN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
77.56M
-7.11%
0.010
-150%
69.45M
-0.22%
-0.030
-175%
79.23M
+1.31%
0.020
-90.83%
Estimates Revision
The market is revising Upward the revenue expectations for The Beauty Health Company (SKIN) for FY2025, with the revenue forecasts being adjusted by 0.69% over the past three months. During the same period, the stock price has changed by -22.93%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-313.33%
In Past 3 Month
Stock Price
Go Down
down Image
-22.93%
In Past 3 Month
Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
0 Sell
Hold
Current: 1.580
sliders
Low
1.50
Averages
2.13
High
3.50
Current: 1.580
sliders
Low
1.50
Averages
2.13
High
3.50
TD Cowen
Oliver Chen
Hold
maintain
$2
2025-09-22
Reason
TD Cowen
Oliver Chen
Price Target
$2
2025-09-22
maintain
Hold
Reason
TD Cowen analyst Oliver Chen raised the firm's price target on Beauty Health to $2.50 from $2 and keeps a Hold rating on the shares. The firm believes the CEO's reset is working on managing device sales (30%) churn and fostering consumables innovation (70%), along with deeper provider engagement in its 35k installed base.
Roth Capital
George Kelly
Buy
initiated
$3.50
2025-09-19
Reason
Roth Capital
George Kelly
Price Target
$3.50
2025-09-19
initiated
Buy
Reason
Roth Capital analyst George Kelly initiated coverage of Beauty Health with a Buy rating and $3.50 price target. The firm is positive on the company's turnaround efforts and believes consensus estimates are too low given the opportunity for more cost-cutting. Further, Beauty Health's growth can improve with the launch of new products in the second half of 2025 and 2026, the analyst tells investors in a research note.
TD Cowen
Oliver Chen
Hold
maintain
$2
2025-05-12
Reason
TD Cowen
Oliver Chen
Price Target
$2
2025-05-12
maintain
Hold
Reason
TD Cowen analyst Oliver Chen raised the firm's price target on Beauty Health to $2 from $1.50 and keeps a Hold rating on the shares. The firm noted Q1 sales declined but management is cautious due to macro and lowered expectations for the remainder of FY25.Cowen views the updated FY25 guide as conservative, but APAC and tariffs remain key pressure points.
Canaccord Genuity
Susan Anderson
Hold
Maintains
$1.75 → $1.5
2025-03-13
Reason
Canaccord Genuity
Susan Anderson
Price Target
$1.75 → $1.5
2025-03-13
Maintains
Hold
Reason
Canaccord lowered the firm's price target on Beauty Health to $1.50 from $1.75 and keeps a Hold rating on the shares. The firm said they reported Q4 sales were lower and although the high- margin consumables business continues to perform well, we continue to see new machine placements severely pressured due to macro conditions.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Beauty Health Co (SKIN.O) is 10.36, compared to its 5-year average forward P/E of 48.21. For a more detailed relative valuation and DCF analysis to assess Beauty Health Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
48.21
Current PE
10.36
Overvalued PE
230.39
Undervalued PE
-133.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
36.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
81.46
Undervalued EV/EBITDA
-8.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.53
Current PS
0.00
Overvalued PS
7.15
Undervalued PS
-0.09
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 87233.33% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SKIN News & Events

Events Timeline

(ET)
2025-09-30
16:33:14
Pedro Malha Named CEO of Beauty Health
select
2025-09-09 (ET)
2025-09-09
08:17:46
Beauty Health Introduces Hydrafacial Advisory Councils and Ambassador Network
select
2025-06-10 (ET)
2025-06-10
08:18:12
Beauty Health launches Hydrafacial HydraFillic with Pep9 Booster
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04Globenewswire
Beauty Health Releases 2025 Skintuition Report, 75% Consumers Prioritize Skin Quality
  • Consumer Trend Shift: The 2025 report reveals that 75% of consumers now prioritize treatments that enhance overall skin quality over volume-enhancing procedures, indicating a significant shift towards skin regeneration in the market.
  • New Product Launch: In June 2025, Hydrafacial introduced the HydraFillic with Pep9™ Booster, a clinically proven booster that visibly improves fine lines and wrinkles, deeply hydrates, and strengthens the skin barrier, addressing the growing consumer demand for skin regeneration.
  • Increased Treatment Frequency: Hydrafacial consumers receive an average of 3.6 treatments per year, demonstrating the brand's success in driving customer return visits and loyalty, thereby solidifying its market position in the aesthetics industry.
  • Clear Market Positioning: The report highlights a rising consumer demand for “notox” and “skinimalism” treatments, and Hydrafacial is aligning with this trend by offering scientifically-backed, safe treatment options that promote a shift towards more natural beauty standards in the industry.
[object Object]
Preview
7.0
12-01PRnewswire
Halper Sadeh Investigates Beauty Health (SKIN) for Potential Fiduciary Breaches
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of The Beauty Health Company (NASDAQ:SKIN) breached their fiduciary duties, potentially impacting corporate governance.
  • Legal Relief Options: Long-term shareholders of Beauty Health may seek corporate governance reforms, fund returns, or court-approved financial awards, aimed at enhancing the company's transparency and accountability.
  • Importance of Shareholder Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value, highlighting the necessity and urgency of effective corporate governance.
  • Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation.
[object Object]
Preview
9.5
11-07NASDAQ.COM
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results

  • Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.

  • Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.

  • Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.

  • ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Beauty Health Co (SKIN) stock price today?

The current price of SKIN is 1.58 USD — it has decreased -0.63 % in the last trading day.

arrow icon

What is Beauty Health Co (SKIN)'s business?

The Beauty Health Company is a medical technology meets beauty company that delivers skin-health experiences. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. It specializes in skin health for all ages, genders, skin tones, and skin types. Its brands include Hydrafacial, SkinStylus, and Keravive. Hydrafacial created the category of hydradermabrasion with its patented delivery system that cleanses, extracts, and hydrates the skin with proprietary solutions and serums. SkinStylus specializes in nanoneedling and microneedling, where its products are designed to provide either a non-invasive (nanoneedling) or minimally invasive (microneedling) skin treatment to individuals. Keravive specializes in scalp health with its products that are designed to support the hair’s natural growth by cleansing, exfoliating, and hydrating the scalp and hair follicles.

arrow icon

What is the price predicton of SKIN Stock?

Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Beauty Health Co (SKIN)'s revenue for the last quarter?

Beauty Health Co revenue for the last quarter amounts to 70.66M USD, decreased -10.34 % YoY.

arrow icon

What is Beauty Health Co (SKIN)'s earnings per share (EPS) for the last quarter?

Beauty Health Co. EPS for the last quarter amounts to -0.09 USD, decreased -40.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Beauty Health Co (SKIN)'s fundamentals?

The market is revising Upward the revenue expectations for The Beauty Health Company (SKIN) for FY2025, with the revenue forecasts being adjusted by 0.69% over the past three months. During the same period, the stock price has changed by -22.93%.
arrow icon

How many employees does Beauty Health Co (SKIN). have?

Beauty Health Co (SKIN) has 769 emplpoyees as of December 05 2025.

arrow icon

What is Beauty Health Co (SKIN) market cap?

Today SKIN has the market capitalization of 201.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free